NASDAQ: FATEFate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?
Insider buying vs selling
Have Fate Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jerome Charles Bressi | Chief Regulatory and Quality Officer | 2025-01-10 | 5,980 | $1.55 | $9.27kSell |
| Cindy Tahl | Chief Legal Compliance Officer and Secretary | 2025-01-10 | 5,654 | $1.55 | $8.76kSell |
| Bahram Valamehr | President and CEO | 2025-01-10 | 8,705 | $1.54 | $13.41kSell |
| Redmile Group LLC | Director | 2024-12-20 | 341,633 | $1.68 | $573.94kSell |
| Redmile Group LLC | Director | 2024-12-20 | 397,964 | $1.68 | $668.58kBuy |
| Redmile Group LLC | Director | 2024-12-20 | 1,084,936 | $1.68 | $1.82MSell |
| Redmile Group LLC | Director | 2024-12-20 | 1,084,936 | $1.68 | $1.82MBuy |
| Yuan Xu | Director | 2024-08-06 | 633 | $4.23 | $2.68kSell |
FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when FATE insiders and whales buy or sell their stock.
FATE Shareholders
What type of owners hold Fate Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Redmile Group LLC | 22.43% | 25,712,223 | $32.78M | Insider |
| Redmile Group LLC | 11.23% | 12,872,946 | $16.41M | Institution |
| Blackrock Inc | 9.32% | 10,681,779 | $13.62M | Institution |
| Vanguard Group Inc | 8.99% | 10,310,453 | $13.15M | Institution |
| Amir Nashat | 8.60% | 9,852,967 | $12.56M | Insider |
| Polaris Venture Management Co V LLC | 8.59% | 9,841,933 | $12.55M | Insider |
| Schonfeld Strategic Advisors LLC | 6.80% | 7,794,513 | $9.94M | Institution |
| Citadel Advisors LLC | 3.74% | 4,289,159 | $5.47M | Institution |
| Jpmorgan Chase Co | 2.96% | 3,398,283 | $4.33M | Institution |
| Johnson Johnson | 2.95% | 3,379,064 | $4.31M | Institution |
FATE vs Biotech Stocks
Fate Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.